Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32


Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation.

Puleston DJ, Buck MD, Klein Geltink RI, Kyle RL, Caputa G, O'Sullivan D, Cameron AM, Castoldi A, Musa Y, Kabat AM, Zhang Y, Flachsmann LJ, Field CS, Patterson AE, Scherer S, Alfei F, Baixauli F, Austin SK, Kelly B, Matsushita M, Curtis JD, Grzes KM, Villa M, Corrado M, Sanin DE, Qiu J, Pällman N, Paz K, Maccari ME, Blazar BR, Mittler G, Buescher JM, Zehn D, Rospert S, Pearce EJ, Balabanov S, Pearce EL.

Cell Metab. 2019 Aug 6;30(2):352-363.e8. doi: 10.1016/j.cmet.2019.05.003. Epub 2019 May 23.


Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein.

Kim AS, Austin SK, Gardner CL, Zuiani A, Reed DS, Trobaugh DW, Sun C, Basore K, Williamson LE, Crowe JE Jr, Slifka MK, Fremont DH, Klimstra WB, Diamond MS.

Nat Microbiol. 2019 Jan;4(1):187-197. doi: 10.1038/s41564-018-0286-4. Epub 2018 Nov 19.


Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.

Batty P, Austin SK, Khair K, Millar CM, Palmer B, Rangarajan S, Stümpel JP, Thanigaikumar M, Yee TT, Hart DP.

Br J Haematol. 2017 Mar;176(5):796-804. doi: 10.1111/bjh.14543. Epub 2017 Feb 15.


Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.

Austin SK, Kavakli K, Norton M, Peyvandi F, Shapiro A; FX Investigators Group.

Haemophilia. 2016 May;22(3):419-25. doi: 10.1111/hae.12893. Epub 2016 Mar 8.


Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.

Austin SK, Brindley C, Kavakli K, Norton M, Shapiro A; FX Investigators Group.

Haemophilia. 2016 May;22(3):426-32. doi: 10.1111/hae.12894. Epub 2016 Feb 15.


Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE Jr, Diamond MS, Rossmann MG.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13898-903. doi: 10.1073/pnas.1515558112. Epub 2015 Oct 26.


Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE Jr.

Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009. Erratum in: Cell Host Microbe. 2015 Sep 9;18(3):382. Khomadiak, Solomiia [corrected to Khomandiak, Solomiia].


Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres.

Batty P, Honke A, Bowles L, Hart DP, Pasi KJ, Uprichard J, Austin SK.

Haemophilia. 2015 Jul;21(4):490-5. doi: 10.1111/hae.12682. Epub 2015 Apr 9.


Structure of acidic pH dengue virus showing the fusogenic glycoprotein trimers.

Zhang X, Sheng J, Austin SK, Hoornweg TE, Smit JM, Kuhn RJ, Diamond MS, Rossmann MG.

J Virol. 2015 Jan;89(1):743-50. doi: 10.1128/JVI.02411-14. Epub 2014 Oct 29.


ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.

Oldenburg J, Austin SK, Kessler CM.

Haemophilia. 2014 Sep;20 Suppl 6:17-26. doi: 10.1111/hae.12466. Review.


Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.

Edeling MA, Austin SK, Shrestha B, Dowd KA, Mukherjee S, Nelson CA, Johnson S, Mabila MN, Christian EA, Rucker J, Pierson TC, Diamond MS, Fremont DH.

PLoS Pathog. 2014 Apr 17;10(4):e1004072. doi: 10.1371/journal.ppat.1004072. eCollection 2014 Apr.


A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding.

Patel YM, Lordkipanidzé M, Lowe GC, Nisar SP, Garner K, Stockley J, Daly ME, Mitchell M, Watson SP, Austin SK, Mundell SJ.

J Thromb Haemost. 2014 May;12(5):716-25. doi: 10.1111/jth.12539.


B cell response and mechanisms of antibody protection to West Nile virus.

Austin SK, Dowd KA.

Viruses. 2014 Mar 3;6(3):1015-36. doi: 10.3390/v6031015. Review.


Neuropathic pain in the general population: a systematic review of epidemiological studies.

van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N.

Pain. 2014 Apr;155(4):654-62. doi: 10.1016/j.pain.2013.11.013. Epub 2013 Nov 26. Review. Erratum in: Pain. 2014 Sep;155(9):1907.


The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.


The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC.

J Virol. 2013 Dec;87(24):13729-40. doi: 10.1128/JVI.02340-13. Epub 2013 Oct 9.


Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13. Epub 2013 Jun 19.


The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1.

Zhou Y, Austin SK, Fremont DH, Yount BL, Huynh JP, de Silva AM, Baric RS, Messer WB.

Virology. 2013 Apr 25;439(1):57-64. doi: 10.1016/j.virol.2013.01.022. Epub 2013 Feb 28.


Mycophenolate mofetil-induced erythroid hypoplasia in a patient with systemic lupus erythematosus.

Doherty T, Austin SK, Newell B, Kiely PD.

Lupus. 2013 Feb;22(2):213-5. doi: 10.1177/0961203312469262. Epub 2012 Dec 20.


Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope.

Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH.

PLoS Pathog. 2012;8(10):e1002930. doi: 10.1371/journal.ppat.1002930. Epub 2012 Oct 4.


Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody.

Shrestha B, Austin SK, Dowd KA, Prasad AN, Youn S, Pierson TC, Fremont DH, Ebel GD, Diamond MS.

Virology. 2012 Jun 5;427(2):127-34. doi: 10.1016/j.virol.2012.02.010. Epub 2012 Mar 9.


Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS.

J Virol. 2010 Oct;84(20):10630-43. doi: 10.1128/JVI.01190-10. Epub 2010 Aug 11.


Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2010 Sep;84(18):9227-39. doi: 10.1128/JVI.01087-10. Epub 2010 Jun 30.


The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS.

PLoS Pathog. 2010 Apr 1;6(4):e1000823. doi: 10.1371/journal.ppat.1000823.


Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.

Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS.

J Virol. 2009 Jul;83(13):6494-507. doi: 10.1128/JVI.00286-09. Epub 2009 Apr 22.


The JAK2 V617F mutation and thrombosis.

Austin SK, Lambert JR.

Br J Haematol. 2008 Nov;143(3):307-20. Review. Erratum in: Br J Haematol. 2008 Nov;143(3):451.


Audit of the peri-delivery use of unfractionated heparin in women on therapeutic low-molecular weight heparin.

Lambert JR, Austin SK, Peebles D, Cohen H.

Br J Haematol. 2008 Jul;142(3):453-6. doi: 10.1111/j.1365-2141.2008.07198.x. Epub 2008 May 24.


The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.

Austin SK, Starke RD, Lawrie AS, Cohen H, Machin SJ, Mackie IJ.

Br J Haematol. 2008 May;141(4):536-44. doi: 10.1111/j.1365-2141.2008.07074.x. Epub 2008 Mar 12.


Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS.

J Virol. 2007 Dec;81(23):12816-26. Epub 2007 Sep 19.


Induction of epitope-specific neutralizing antibodies against West Nile virus.

Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2007 Nov;81(21):11828-39. Epub 2007 Aug 22.


Pregnancy loss, tissue factor pathway inhibitor deficiency and resistance to activated protein C.

Gardiner C, Cohen H, Austin SK, Machin SJ, Mackie IJ.

J Thromb Haemost. 2006 Dec;4(12):2724-6. Epub 2006 Sep 6. No abstract available.


Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin.

Panchapakesan U, Austin SK, Shafransky A, Lawrence JA, Savdie E.

Intern Med J. 2003 Sep-Oct;33(9-10):468-71.


Supplemental Content

Loading ...
Support Center